LPL and diffuse large B-cell lymphoma: The unadjusted five-year RS rates were highest for de novo DLBCL at 68%, followed by t-EMZL (61%), t-FL (58%), t-NMZL (56%), t-SMZL (54%), and T-LPL/WM (36%) (Table 3).